insights_auto
Why is ALNOV down 4.66%?
Dive Deeperchevron_right
ALNOV:EPA
Novacyt SA
€0.45
arrow_downward
-4.66%(-0.022) 1D
Oct 2, 5:35:11 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.46
High
€0.47
Low
€0.44
Mkt. cap
30.08M
Avg. vol.
259.52K
Volume
271.08K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.39
Shares outstanding
72.59M
No. of employees
216
Open
€0.46
High
€0.47
Low
€0.44
Mkt. cap
30.08M
Avg. vol.
259.52K
Volume
271.08K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.39
Shares outstanding
72.59M
No. of employees
216
News stories
From web sources and news partners
Yahoo Finance
·
1 day ago
Novacyt SA (NVYTF) (Q2 2026) Earnings Call Highlights: Revenue Jumps to GBP11. ...
TipRanks
·
1 day ago
Novacyt S.A. Earnings Call Signals Cost-Driven Shift
www.marketscreener.com
·
3 days ago
Novacyt S.A. Reports Earnings Results for the Half Year Ended June 30, 2026
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA